Precirix adds Simone Botti, Sabine Dandiguian and Jasper Bos to Board along with raising €80m Series B funding co-led by INKEF Capital, Jeito Capital and Forbion
– BELGIUM, Brussels – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announced the closing of an €80m Series B financing round led by INKEF Capital alongside Jeito Capital and Forbion.